Hypertension trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Hypertension. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month5 studies across 5 companies, in the next 180 days.
August 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | A Study of LY3971297 in Healthy ParticipantsNCT06148272Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Active, not recruiting | Aug 2026 | ≤ 11 d | 2026-07-16 |
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| VNDA | Vanda Pharmaceuticals | Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionNCT07090161Change from baseline to treatment week 4 in SiSBP | Phase 2 | Recruiting | Oct 2026 | ≤ 72 d | 2026-02-27 |
December 2026 3
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| KARD | Kardigan, Inc. | Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe HypertensionNCT07511361Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions | Phase 2 | Recruiting | Dec 2026 | ≤ 133 d | 2026-07-01 |
| OBIO | Orchestra BioMed, Inc | BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenTNCT06059638Change from Baseline in the Mean 24-hour ambulatory systolic blood pressure (aSBP) at 3 Months | Not applicable | Recruiting | Dec 2026 | ≤ 133 d | 2026-07-09 |
| UTHR | United Therapeutics | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionNCT03683186Number of subjects with treatment-emergent adverse events [Safety and Tolerability] | Phase 3 | Enrolling by invitation | Dec 2026 | ≤ 133 d | 2026-02-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Hypertension
most recently updated first365 studies match. Showing the first 100 of 365 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals | $30.6B | Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular DiseaseNCT07181109Time to First Occurrence of a Composite Endpoint of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, or Heart Failure (HF) Event (Hospitalization for HF or Urgent HF Visit) | Phase 3 | Recruiting | Drug: Zilebesiran, Placebo | High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk | 11,000 | 2025-09-22 | 2030-09-30 | in 1,502 d | 2026-08-19 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With ZilebesiranNCT07553442Part A: Percentage recovery from baseline in serum AGT | Phase 2 | Recruiting | Drug: ALN-AGT01 RVR, Placebo, Zilebesiran | Hypertension | 93 | 2026-04-27 | 2028-04-01 | in 590 d | 2026-08-14 |
| CRSP | CRISPR Therapeutics AG | $5.1B | A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With HypertensionNCT07758634Phase 1: Incidence of dose-limiting toxicities (DLTs) | Phase 1/2 | Recruiting | Drug: CTX340, Placebo | Hypertension | 69 | 2026-08-08 | 2028-07-01 | in 681 d | 2026-08-11 |
| AZN | AstraZeneca | — | A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant HypertensionNCT06168409results2026-08-06Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy | Phase 3 | Completed | Drug: Baxdrostat, Placebo | Resistant Hypertension | 218 | 2024-03-01 | 2025-08-17actual | — | 2026-08-06 |
| AZN | AstraZeneca | — | A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionNCT06034743results2026-07-30Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat | Phase 3 | Completed | Drug: Baxdrostat, Placebo | Uncontrolled Hypertension, Resistant Hypertension | 796 | 2023-11-22 | 2025-05-21actual | — | 2026-07-30 |
| MLYS | Mineralys Therapeutics Inc. | $2.3B | Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionNCT05968430Change from MLS-101-301 baseline automated office blood pressure | Phase 3 | Active, not recruiting | Drug: lorundrostat, Placebo | Hypertension | 1,076 | 2023-07-14 | 2025-12-30actual | — | 2026-07-24 |
| AZN | AstraZeneca | — | Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care SystemNCT07361276observationalUncontrolled blood pressure | — | Recruiting | — | Hypertension | 15,000 | 2026-03-31 | 2026-07-31 | — | 2026-07-24 |
| AZN | AstraZeneca | — | iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic DiseasesNCT03549754observational1. Age of particpants | — | Recruiting | — | Type 2 Diabetes, Hypertension, Chronic Kidney Disease, Heart Failure | 35,000 | 2018-02-17 | 2030-12-31 | in 1,594 d | 2026-07-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3971297 in Healthy ParticipantsNCT06148272Part A and F: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Active, not recruiting | Drug: LY3971297, Placebo, LY3971297 IV | Healthy, Obesity, Hypertension | 225 | 2023-12-07 | Aug 2026 | ≤ 11 d | 2026-07-16 |
| OBIO | Orchestra BioMed, Inc | $340M | BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenTNCT06059638Change from Baseline in the Mean 24-hour ambulatory systolic blood pressure (aSBP) at 3 Months | Not applicable | Recruiting | Device: Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated, Medtronic Astra/Azure DR MRI IPG with AVIM therapy Deactivated | Hypertension, Hypertension, Systolic, Hypertension, Essential | 500 | 2023-12-27 | Dec 2026 | ≤ 133 d | 2026-07-09 |
| AZN | AstraZeneca | — | A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.NCT07686120Change from baseline in ambulatory 24-hour average Systolic blood pressure(SBP) at Week 12 | Phase 3 | Not yet recruiting | Drug: baxdrostat 2mg, Placebo 2mg | Uncontrolled Hypertension | 286 | 2026-09-30 | 2028-02-09 | in 538 d | 2026-07-07 |
| KARD | Kardigan, Inc. | $1.9B | Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe HypertensionNCT07511361Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions | Phase 2 | Recruiting | Drug: Tonlamarsen, Placebo | Hypertension, Acute Severe Hypertension, Hypertensive Emergency, Hypertensive Urgency | 140 | 2026-06-23 | Dec 2026 | ≤ 133 d | 2026-07-01 |
| UTHR | United Therapeutics | $22.2B | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH PatientsNCT03626688Time from randomization to the first adjudicated protocol-defined clinical worsening event | Phase 3 | Completed | Drug: Ralinepag, Placebo | PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease | 687 | 2019-01-24 | 2025-12-31actual | — | 2026-06-16 |
| GAIA | Gaia AG | $36M | Effectiveness of a Digital Health Application for Primary Hypertension (Liebria)NCT06243978SBP (in mmHg) | Not applicable | Active, not recruiting | Behavioral: liebria · Other: information brochure on hypertension | Hypertension | 328 | 2024-04-02 | Jun 2026 | — | 2026-06-16 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)NCT06948422Number of Participants Allocated to Each ISA | Phase 3 | Active, not recruiting | Drug: Orforglipron, Placebo | Hypertension | 974 | 2025-04-30 | Sep 2027 | ≤ 406 d | 2026-05-29 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1NCT06948435Change from Baseline in office Systolic Blood Pressure (SBP) | Phase 3 | Active, not recruiting | Drug: Orforglipron, Placebo | Hypertension, Overweight or Obesity | 487 | 2025-04-30 | Sep 2027 | ≤ 406 d | 2026-05-29 |
| LLY | Eli Lilly and Company | $1.15T | A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2NCT06952530Change from Baseline in office Systolic Blood Pressure (SBP) | Phase 3 | Active, not recruiting | Drug: Orforglipron, Placebo | Hypertension | 487 | 2025-04-30 | Sep 2027 | ≤ 406 d | 2026-05-29 |
| MLYS | Mineralys Therapeutics Inc. | $2.3B | Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionNCT06153693Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo | Phase 3 | Completed | Drug: Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Hypertension | 1,083 | 2023-11-22 | 2024-12-10actual | — | 2026-05-01 |
| AZN | AstraZeneca | — | A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionNCT06344104Change from baseline in seated SBP at Week 12 | Phase 3 | Completed | Drug: Baxdrostat, Placebo | Uncontrolled Hypertension, Resistant Hypertension | 326 | 2024-04-08 | 2025-11-24actual | — | 2026-04-21 |
| KARD | Kardigan, Inc. | $1.9B | A Study to Investigate Tonlamarsen for the Treatment of Adults With Uncontrolled Hypertension (KARDINAL)NCT06864104To assess the effect of tonlamarsen on plasma angiotensinogen (AGT) levels | Phase 2 | Completed | Drug: Tonlamarsen, Placebo | Hypertension | 206 | 2025-04-10 | 2026-01-12actual | — | 2026-03-31 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)NCT06272487Change from Baseline at Month 3 in Mean Seated Office Systolic Blood Pressure (SBP) | Phase 2 | Completed | Drug: Zilebesiran, Placebo | High Cardiovascular Risk, Hypertension | 375 | 2024-02-29 | 2025-06-19actual | — | 2026-03-02 |
| VNDA | Vanda Pharmaceuticals | $329M | Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled HypertensionNCT07090161Change from baseline to treatment week 4 in SiSBP | Phase 2 | Recruiting | Drug: iloperidone, Placebo | Hypertension, Uncontrolled Hypertension | 240 | 2025-09-15 | Oct 2026 | ≤ 72 d | 2026-02-27 |
| UTHR | United Therapeutics | $22.2B | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionNCT03683186Number of subjects with treatment-emergent adverse events [Safety and Tolerability] | Phase 3 | Enrolling by invitation | Drug: Ralinepag | PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease | 1,000 | 2019-09-23 | Dec 2026 | ≤ 133 d | 2026-02-20 |
| CORT | Corcept Therapeutics | $12.8B | Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)NCT06829537observationalTo assess the prevalence of endogenous hypercortisolism in a population with resistant hypertension. | — | Completed | — | Resistant Hypertension, Hypercortisolism | 1,143 | 2025-03-28 | 2025-12-08actual | — | 2026-02-17 |
| 000100.KS | Yuhan Corporation | $4.2B | Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential HypertensionNCT06041529Mean Systolic Blood Pressure (MSBP) in nighttime | Phase 4 | Active, not recruiting | Drug: Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg, Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg | Essential Hypertension | 198 | 2023-10-18 | 2026-02-28 | — | 2026-02-13 |
| MLYS | Mineralys Therapeutics Inc. | $2.3B | A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication RegimenNCT05769608Change in 24-hour average ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP) | Phase 2 | Completed | Drug: Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Hypertension | 285 | 2023-03-13 | 2025-01-15actual | — | 2026-01-20 |
| MLYS | Mineralys Therapeutics Inc. | $2.3B | A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and HypertensionNCT06785454Placebo-adjusted Change From Baseline in AHI at Week 4 | Phase 2 | Completed | Drug: Lorundrostat, Placebo | Obstructive Sleep Apnea, Hypertension | 48 | 2025-02-28 | 2025-12-17actual | — | 2026-01-13 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate HypertensionNCT04936035results2024-12-27Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM | Phase 2 | Completed | Drug: Placebo, ALN-AGT01 | Hypertension | 394 | 2021-07-07 | 2023-04-04actual | — | 2025-12-23 |
| AZN | AstraZeneca | — | A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled HypertensionNCT06336356results2025-12-17Number of Participants With Serum Total Cortisol Level Before and After Adrenocorticotropic Hormone (ACTH) Stimulation Test | Phase 2 | Completed | Drug: Baxdrostat, Placebo | Uncontrolled Hypertension | 48 | 2024-06-10 | 2024-12-04actual | — | 2025-12-17 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)NCT05103332results2025-07-09Indapamide: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM - Censored Data | Phase 2 | Completed | Drug: Indapamide, Amlodipine, Olmesartan, Placebo, Zilebesiran | Hypertension | 663 | 2021-11-05 | 2023-12-11actual | — | 2025-11-03 |
| REGN | Regeneron Pharmaceuticals | $76.1B | REGN5381 in Adult Participants With Uncontrolled HypertensionNCT06833190Unattended Automated Office-Based Blood Pressure (AOBP) Systolic Blood Pressure (SBP) | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: REGN5381, Placebo | Uncontrolled Hypertension | 34 | 2025-04-16 | 2025-10-15actual | — | 2025-10-23 |
| 068270.KS | Celltrion | $30.7B | Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive SubjectsNCT05385770msitSBP | Phase 3 | Completed | Drug: AZM X mg + AML Y mg, AZM X mg + AML Y' mg, AZM X' mg + AML Y mg, AZM X' mg + AML Y' mg, AZM X mg, AZM X' mg, AML Y mg, AML Y' mg | Essential Hypertension | 890 | 2022-07-08 | 2024-07-11actual | — | 2025-09-11 |
| CVRX | CVRx, Inc. | $73M | Verification of the Efficacy and Safety of the BAROSTIM NEO System in the Treatment of Drug Resistant HypertensionNCT01471834To access long-term adverse events in participants implanted with the BAROSTIM NEO System. | Not applicable | Active, not recruiting | Device: BAROSTIM NEO System · Drug: Medical Management | High Blood Pressure | 40 | Jun 2011 | May 2012actual | — | 2025-07-15 |
| CVRX | CVRx, Inc. | $73M | BAROSTIM NEO Hypertension Pivotal TrialNCT01679132To assess long-term adverse events in subjects implanted with the BAROSTIM NEO System. | Not applicable | Suspendedsponsor's stated reason: Company resources only allows adequate oversight for one pivotal trial at a time | Device: BAROSTIM NEO System and Medical Management | Uncontrolled Hypertension | 10 | 2013-04-12 | Mar 2026 | — | 2025-07-15 |
| AZN | AstraZeneca | — | A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney DiseaseNCT05432167results2025-05-20Change From Baseline in Mean Seated Systolic Blood Pressure (SBP) of Pooled CIN-107 and Placebo | Phase 2 | Completed | Drug: CIN-107, Placebo | Uncontrolled Hypertension, Chronic Kidney Diseases | 195 | 2022-04-29 | 2024-05-02actual | — | 2025-05-20 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Hypertensive Participants With Uncontrolled Blood PressureNCT04714320results2025-02-18Change From Baseline in Seated Automated Office SBP to Day 85 | Phase 2 | Completed | Drug: Placebo, IONIS-AGT-LRx | Hypertension | 160 | 2021-04-28 | 2022-06-29actual | — | 2025-02-18 |
| NUE | Nucor | $59.9B | A Comprehensive Optical Blood Pressure Assessment Tool to Identify Cases of Unscreened Hypertension Across an Active Population in the U.S.NCT06721611observationalThe percentage of subjects with undiagnosed hypertension | — | Withdrawnsponsor's stated reason: The study was aborted by the sponsor. | Device: Optical Blood Pressure Monitoring Device (Aktiia G1) | Hypertension | 0 | 2025-01-16 | 2025-07-16 | — | 2025-02-06 |
| 000100.KS | Yuhan Corporation | $4.2B | Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and HypercholesterolemiaNCT06293261observationalOccurence rate of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) | — | Completed | Drug: Rosuampin 5/5mg, 10/5mg, 20/5mg, 10/10mg | Hypertension, Hypercholesterolemia | 5,047 | 2020-06-27 | 2024-03-31actual | — | 2025-01-22 |
| AZN | AstraZeneca | — | Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124NCT05459688results2024-12-16Number of Participants With Any Treatment-emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: CIN-107 | Hypertension | 175 | 2022-04-06 | 2023-11-07actual | — | 2024-12-16 |
| 000100.KS | Yuhan Corporation | $4.2B | Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential HypertensionNCT06282549observationalPercentage of MACCE(Major Adverse Cardiovascular and Cerebrovascular Events) | — | Active, not recruiting | Drug: Telmisartan/Amlodipine/Chlorthalidone(Truset) | Essential Hypertension | 1,219 | 2022-06-08 | 2027-03-31 | in 223 d | 2024-11-19 |
| 000100.KS | Yuhan Corporation | $4.2B | Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine TreatmentNCT02620163Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 | Phase 3 | Completed | Drug: telmisartan/amlodipine 40/5mg, YH22162 40/5/12.5 mg, telmisartan/amlodipine 80/5mg, YH22162 80/5/25 mg, telmisartan/amlodipine 40/5mg placebo, YH22162 40/5/12.5 mg placebo, telmisartan/amlodipine 80/5mg placebo, YH22162 80/5/25 mg placebo | Hypertension | 381 | Dec 2015 | Dec 2016actual | — | 2024-11-12 |
| 000100.KS | Yuhan Corporation | $4.2B | Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Healthy VolunteersNCT03662620AUClast of Telmisartan/amlodipine/chlorthalidone | Phase 1 | Completed | Drug: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg, Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg | Hypertension | 67 | 2018-10-05 | 2018-12-08actual | — | 2024-11-12 |
| OGN | Organon and Co | $3.6B | ALLOGRAFT, A Study to Evaluate the Renal Protective Effects of Losartan (0954-222)(COMPLETED)NCT00140907Incidence of chronic allograft nephropathy | Phase 4 | Completed | Drug: losartan potassium, Comparator: Placebo | High Blood Pressure | 367 | 2000-03-14 | 2005-01-01actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | Losartan and HCTZ and Amlodipine vs Atenolol and Amlodipine (0954A-309)(COMPLETED)NCT00140959Mean daytime ambulatory systolic blood pressure | Phase 4 | Completed | Drug: MK0954, losartan potassium/Duration of Treatment: 18 weeks, Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks | Hypertension | 120 | 2003-02-01 | 2004-06-30actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)NCT00157963Antihypertensive efficacy of 12 weeks of treatment with hydrochlorothiazide (+) losartan potassium/amlodipine | Phase 4 | Completed | Drug: MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks | Essential Hypertension | 174 | 2005-02-05 | 2006-02-08actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | Evaluation of the Antihypertensive Effect of Hyzaar(R) and Cognitive Function of Hypertensive Patients (0954A-322)NCT00398541Neuropsychological tests and blood pressure after treatment of 12 weeks | Phase 3 | Completed | Drug: losartan potassium (+) hydrochlorothiazide | Hypertension | 41 | 2005-03-01 | 2007-04-10actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)NCT00400218Blood pressure over 12 weeks | Phase 3 | Completed | Drug: MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks | Hypertension | 62 | 2005-09-01 | 2006-07-01actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)NCT00449111Change of diastolic blood pressure after 6 weeks of treatment with cozaar plus | Phase 3 | Terminated | Drug: MK0954, losartan potassium / Duration of Treatment - 12 weeks | Hypertension | 11 | 2006-03-13 | 2006-09-30actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)NCT00480805To determine the antihypertensive effectiveness of HYZAAR as compared to Ramipril as measure by SiSBP at Week 4 | Phase 3 | Completed | Drug: MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks, Comparator : ramipril /Duration of Treatment : 8 Weeks | Type 2 Diabetes Mellitus, Hypertension | 312 | 2001-08-08 | 2002-10-15actual | — | 2024-08-15 |
| OGN | Organon and Co | $3.6B | Health Assessment Study (0954-946)NCT00541684number of sexual intercourse events in a 2-week period | Phase 3 | Completed | Drug: MK0954, /Duration of Treatment : 16 Weeks, Comparator : atenolol /Duration of Treatment : 16 Weeks | Hypertension | 143 | 2001-07-11 | 2003-01-23actual | — | 2024-08-15 |
| PFE | Pfizer | $155.3B | Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride CapsulesNCT04967443results2024-07-12Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Prazosin | Phase 1 | Completed | Drug: Prazosin HCl 2mg, Prazosin HCl 1 mg, Prazosin HCl 5 mg | Hypertension, Heart Failure | 72 | 2021-09-22 | 2022-02-15actual | — | 2024-07-12 |
| OGN | Organon and Co | $3.6B | Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399)NCT01277822results2014-04-24Change in Mean Sitting Diastolic Blood Pressure (MSDBP) at Week 8 | Phase 4 | Completed | Drug: Losartan (+) amlodipine, Placebo to match losartan/amlodipine tablets, Amlodipine camsylate, Placebo to match amlodipine | Hypertension | 334 | 2011-05-30 | 2013-04-22actual | — | 2024-06-20 |
| OGN | Organon and Co | $3.6B | A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327)NCT00447603results2014-03-05Change From Baseline in Sitting Trough Systolic Blood Pressure (SiSBP) at Week 4 of Double-blind Treatment Period | Phase 3 | Terminatedsponsor's stated reason: Achieving site readiness and enrolling the trial within a reasonable time | Drug: hydrochlorothiazide (+) losartan potassium, losartan potassium, Placebo for Losartan, Placebo for Losartan/HCTZ | Hypertension | 40 | 2007-05-24 | 2007-10-22actual | — | 2024-06-18 |
| OGN | Organon and Co | $3.6B | Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)NCT00756938results2014-03-03Mean Change From Baseline in Systolic Blood Pressure | Phase 3 | Completed | Drug: losartan potassium | Hypertension | 101 | 2009-03-01 | 2012-08-14actual | — | 2024-06-18 |
| OGN | Organon and Co | $3.6B | LAAS (Losartan Anti-Atherosclerosis Study)(0954-330)(COMPLETED)NCT00496834results2010-12-15Pulse Wave Velocity (PWV) Changes From Baseline (Visit 2) to 24 Weeks (Visit 6) After the Administration of the Study Drug | Phase 4 | Completed | Drug: losartan potassium, Comparator: carvedilol, Comparator: losartan (+) hydrochlorothiazide (HCTZ), Comparator: carvedilol (+) hydrochlorothiazide | Hypertension | 201 | 2008-02-01 | 2009-09-01actual | — | 2024-05-22 |
| OGN | Organon and Co | $3.6B | A Study of Safety and Efficacy in MK-0954A Combination in Participants With Hypertension (MK-0954A-373 AM3)NCT01431508results2011-11-22Mean Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 | Phase 4 | Completed | Drug: Losartan 50 mg / HCTZ 12.5 mg | Hypertension | 15 | 2007-08-01 | 2009-06-01actual | — | 2024-05-22 |
| OGN | Organon and Co | $3.6B | A Long-term Study of the Safety of MK-0954A in Patients With Essential Hypertension (MK-0954A-351)NCT01307033results2014-01-06Percentage of Participants Who Experienced an Adverse Event When Receiving MK-0954A (L100/H12.5) During Study (8-week Double-blind and/or 44-week Open-label Extension) | Phase 3 | Completed | Drug: MK-0954A, MK-954H, Placebo to MK-0954A, Placebo to MK-954H | Hypertension | 278 | 2011-03-29 | 2012-12-04actual | — | 2024-05-17 |
| OGN | Organon and Co | $3.6B | MK-0954A in Japanese Patients With Essential Hypertension Not Adequately Controlled With Losartan (MK-0954A-352)NCT01307046results2013-03-22Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) | Phase 3 | Completed | Drug: MK-0954A, Losartan, Placebo to MK-0954A, Placebo to losartan 100 mg, Placebo to losartan 50 mg | Hypertension | 336 | 2011-03-29 | 2012-02-07actual | — | 2024-05-17 |
| OGN | Organon and Co | $3.6B | A 52 Week Study to Evaluate the Effects of Losartan With or Without HCTZ on Plasma Glucose, Metabolic Parameters, Blood Pressure in Hypertensive Patients With Metabolic Syndrome (0954A-331)NCT00546052results2009-06-23Change in Hemoglobin A1c Between 52 Weeks and Baseline | Phase 3 | Completed | Drug: losartan potassium (+) hydrochlorothiazide | Hypertension, Metabolic Disorder | 1,738 | 2005-09-01 | 2008-01-01actual | — | 2024-05-16 |
| OGN | Organon and Co | $3.6B | BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)NCT00546754results2010-04-13Change in Systolic Blood Pressure From Baseline to Week 12 | Phase 3 | Completed | Drug: losartan potassium (+) hydrochlorothiazide, Comparator: Valsartan (+) Hydrochlorothiazide | Hypertension | 808 | 2007-05-01 | 2009-04-01actual | — | 2024-05-16 |
| OGN | Organon and Co | $3.6B | SAALT: Subtracting Salt and Adding Losartan Trial (0954A-335)NCT00739674results2010-08-11Number of Patients Achieving Target Blood Pressure at Week 14 From Baseline | Phase 3 | Completed | Drug: losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB]) · Behavioral: Low Salt Diet | Hypertension | 992 | 2008-02-01 | 2009-07-01actual | — | 2024-05-16 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled HypertensionNCT05314439Percent Change from Baseline in Plasma Angiotensinogen (AGT) | Phase 2 | Completed | Drug: ION904, Placebo | Hypertension | 48 | 2022-04-29 | 2023-01-31actual | — | 2023-12-22 |
| NVS | Novartis | — | Efficacy and Safety of Valsartan/Amlodipine Combination in Hypertensive Patients Not Controlled With Amlodipine AloneNCT00171002Change from baseline in diastolic blood pressure after 8 weeks | Phase 3 | Completed | Drug: valsartan/amlodipine | Hypertension | 936 | Nov 2004 | Jun 2005actual | — | 2023-12-14 |
| NVS | Novartis | — | Efficacy and Safety of Valsartan and the Combination of Valsartan and SimvastatinNCT00385931Change from baseline in ambulatory systolic blood pressure at 12 weeks | Phase 3 | Completed | Drug: Valsartan and simvastatin | Hypertension, Hypercholesterolemia, Dyslipidemia | 412 | Jan 2002 | Apr 2003actual | — | 2023-11-09 |
| NVS | Novartis | — | Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic HypertensionNCT00170950results2011-05-17Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event | Phase 3 | Terminatedsponsor's stated reason: The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment. | Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter | Hypertension | 11,506 | Oct 2003 | Jan 2008actual | — | 2023-10-24 |
| NVS | Novartis | — | VALORY Study of Valsartan/Hydrochlorizide for Patients Who do Not Respond Adequately to Olmesartan MedoxomilNCT00171015Change from baseline in diastolic blood pressure after 4 weeks | Phase 3 | Completed | Drug: valsartan plus hydrochlorothiazide | Hypertension | 212 | Dec 2004 | Apr 2005actual | — | 2023-10-18 |
| NVS | Novartis | — | The VALIDATE Study of Valsartan for Patients With Early Stage Heart FailureNCT00241098Change from baseline in a blood measurement for heart failure after 26 weeks | Phase 4 | Completed | Drug: valsartan | Hypertension, Congestive Heart Failure | 37 | May 2003 | Jun 2005actual | — | 2023-10-18 |
| NVS | Novartis | — | A Year Long Study to Evaluate the Safety of the Combination of Valsartan (320 mg) and Amlodipine (5 mg) in Patients With HypertensionNCT00170976Adverse events and serious adverse events at each study visit for 6 or 12 months | Phase 3 | Completed | Drug: valsartan + amlodipine | HYPERTENSION | 403 | Apr 2004 | Jun 2005actual | — | 2023-10-12 |
| NVS | Novartis | — | Hypertension and Cardiovascular Risk FactorsNCT00171782Change from baseline systolic blood pressure at 8 weeks | Phase 4 | Completed | Drug: VALSARTAN+HYDROCHLOROTHIAZIDE | HYPERTENSION | 76 | Feb 2004 | Dec 2004actual | — | 2023-10-12 |
| NVS | Novartis | — | Safety and Efficacy of Valsartan and Amlodipine Combined and Alone in Patients With Hypertension.NCT00409760Change from baseline (Visit 2) in mean sitting diastolic blood pressure at trough (Wk 4 and Wk 8) | Phase 3 | Completed | Drug: valsartan+amlodipine combination, valsartan, amlodipine | Hypertension | 1,930 | Jan 2003 | Feb 2004actual | — | 2023-10-12 |
| APMD | Apnimed | — | Trial of AD113 and Atomoxetine in OSA Patients With HypertensionNCT04905979Change in hypoxic burden (HB, total area under the respiratory event-related desaturation curve) | Phase 2 | Completed | Drug: AD113, Atomoxetine | Obstructive Sleep Apnea, Hypertension | 21 | 2021-07-31 | 2023-01-31actual | — | 2023-08-21 |
| AZN | AstraZeneca | — | Phase 1 Study to Determine the Metabolism and Clearance of BaxdrostatNCT05961384Total radioactivity recovery in urine and feces following administration of [14C] baxdrostat. | Phase 1 | Completed | Drug: baxdrostat | Hypertension | 8 | 2021-11-18 | 2022-01-15actual | — | 2023-08-15 |
| 068270.KS | Celltrion | $30.7B | A Bioequivalence Study of L04TD3 Compared to Administration of L04RD1 in Healthy VolunteersNCT05993806AUCt | Phase 1 | Completed | Drug: L04RD1, L04TD3 | Essential Hypertension | 50 | 2023-06-02 | 2023-06-12actual | — | 2023-08-15 |
| AZN | AstraZeneca | — | Study to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal FunctionNCT05470725Maximum plasma concentration (Cmax) | Phase 1 | Completed | Drug: CIN-107 | Hypertension | 33 | 2021-01-12 | 2021-04-30actual | — | 2023-08-14 |
| AZN | AstraZeneca | — | Study With CIN-107 Following Multiple Oral Ascending Doses in Healthy SubjectsNCT05500820Maximum plasma concentration (Cmax) | Phase 1 | Completed | Drug: CIN-107, Matching Placebo | Hypertension | 56 | 2019-12-19 | 2020-04-03actual | — | 2023-08-14 |
| AZN | AstraZeneca | — | Study to Evaluate the Effect of CIN-107 on the Pharmacokinetics of the MATE Substrate, Metformin, in Healthy SubjectsNCT05526690Maximum plasma concentration (Cmax) | Phase 1 | Completed | Drug: Metformin, CIN-107 | Hypertension | 27 | 2020-10-28 | 2020-12-12actual | — | 2023-08-14 |
| AZN | AstraZeneca | — | Phase 1 PK Study to Evaluate the PK of CIN-107 in Subjects With Hepatic ImpairmentNCT05961397Incidence of treatment emergent adverse events following administration of a single oral dose of baxdrostat to subjects with varying degrees of hepatic function. | Phase 1 | Completed | Drug: baxdrostat | Hypertension | 20 | 2021-08-10 | 2022-04-15actual | — | 2023-08-14 |
| AZN | AstraZeneca | — | Baxdrostat Bioavailability and Bioequivalence StudyNCT05963009Incidence of treatment emergent adverse events following single oral doses of CIN-107 tablet and oral solution. | Phase 1 | Completed | Drug: baxdrostat (formerly CIN-107) oral solution | Hypertension | 14 | 2020-03-11 | 2020-04-29actual | — | 2023-08-14 |
| AZN | AstraZeneca | — | Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese PopulationNCT05966324Incidence of treatment emergent adverse events following single and multiple doses of baxdrostat in healthy Japanese and Caucasian participants versus placebo recipients. | Phase 1 | Completed | Drug: baxdrostat | Hypertension | 41 | 2022-07-05 | 2022-09-20actual | — | 2023-08-14 |
| CVRX | CVRx, Inc. | $73M | BAROSTIM THERAPY™ In Resistant HypertensionNCT02880631observationalBlood Pressure Changes | — | Unknown status | Device: BAROSTIM NEO™ System | Hypertension | 500 | 2016-12-13 | Jul 2024 | — | 2023-04-20 |
| ESPR | Esperion Therapeutics, Inc. | — | Evaluation of ETC-1002 in Participants With Hypercholesterolemia and HypertensionNCT02178098results2023-04-04Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol (LDL-C) to Week 6 | Phase 2 | Completed | Drug: ETC-1002, Placebo | Hypercholesterolemia, Hypertension | 143 | 2014-06-16 | 2015-05-22actual | — | 2023-04-04 |
| WINT | Windtree Therapeutics | $37,080 | Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With LosartanNCT03217825Systolic Blood Pressure | Phase 2 | Completed | Drug: Rostafuroxin, Losartan | Hypertension | 240 | Dec 2015 | 2018-02-08actual | — | 2023-02-21 |
| IONS | Ionis Pharmaceuticals, Inc. | $9.9B | A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRxNCT04083222results2023-01-18Percent Change From Baseline in Plasma Angiotensinogen (AGT) at Day 57 Compared to Placebo | Phase 2 | Completed | Drug: Placebo, ISIS 757456 | Hypertension | 26 | 2019-11-13 | 2020-07-20actual | — | 2023-01-18 |
| ALNY | Alnylam Pharmaceuticals | $30.6B | A Study to Evaluate ALN-AGT01 in Patients With HypertensionNCT03934307Number of Participants with Adverse Events (AEs) | Phase 1 | Completed | Drug: ALN-AGT01, ALN-AGT01-Matching Placebo, Irbesartan, Irbesartan-Matching Placebo | Hypertension | 124 | 2019-05-01 | 2022-04-20actual | — | 2023-01-17 |
| 000100.KS | Yuhan Corporation | $4.2B | Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With DyslipidemiaNCT03951207Rate of change from baseline to week 8 in LDL-Cholesterol | Phase 4 | Completed | Drug: Rosuampin 10/5mg, Rosuampin 20/5mg, Amlodipine/Atorvastatin 5/20mg | Dyslipidemias, Hypertension | 259 | 2019-05-30 | 2021-09-29actual | — | 2022-10-12 |
| OGN | Organon and Co | $3.6B | Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)NCT00092209Mean trough SiDBP after 8 weeks of treatment | Phase 3 | Completed | Drug: MK0954A, hydrochlorothiazide (+) losartan potassium, Comparator: placebo, losartan, hydrochlorothiazide | Hypertension | 840 | Apr 2002 | Nov 2002actual | — | 2022-02-15 |
| OGN | Organon and Co | $3.6B | Cozaar XQ Re-examination Study (MK-0954-349)NCT01041807observationalNumber of participants with any adverse experience | — | Completed | Drug: amlodipine/losartan | Hypertension | 669 | Feb 2010 | Mar 2015actual | — | 2022-02-15 |
| OGN | Organon and Co | $3.6B | Obese Hypertension Study (0954-315)NCT00289887results2010-05-27Mean Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 8 | Phase 3 | Completed | Drug: Comparator: losartan +/- HCTZ, Comparator: Placebo | Hypertension | 261 | Feb 2006 | Feb 2007actual | — | 2022-02-09 |
| OGN | Organon and Co | $3.6B | The Effect of Losartan and Losartan Plus Isosorbide Mononitrate on Central Blood Pressure Measurements (0954-317)NCT00943852results2010-07-15Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg | Phase 1 | Completed | Drug: losartan potassium, Comparator: isosorbide mononitrate (ISMN), Comparator: losartan + ISMN, Comparator: losartan + ISMN, Comparator: Placebo | Hypertension | 13 | Aug 2006 | Dec 2006actual | — | 2022-02-09 |
| OGN | Organon and Co | $3.6B | Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)NCT00953680results2010-07-16Area Under the Curve (AUC(0 to Infinity)) of Losartan | Phase 1 | Completed | Drug: losartan potassium (+) hydrochlorothiazide (HCTZ), losartan potassium, hydrochlorothiazide (HCTZ) | Hypertension | 77 | Apr 2004 | May 2004actual | — | 2022-02-09 |
| OGN | Organon and Co | $3.6B | Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)NCT01368185results2011-09-01observationalSerum Uric Acid (SUA) Level | — | Completed | — | Hypertension | 1,705 | Nov 2008 | Aug 2010actual | — | 2022-02-09 |
| OGN | Organon and Co | $3.6B | A Study to Evaluate Whether Losartan Protects the Kidney in Hypertensive Diabetic Participants With Microalbuminuria (MK0954-365 AM1)NCT01390415results2011-09-13observationalNumber of Participants With Macroalbuminuria After 6 Months of Treatment | — | Completed | — | Hypertension | 136 | Sep 2008 | Aug 2010actual | — | 2022-02-09 |
| PFE | Pfizer | $155.3B | A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood PressureNCT00422461results2021-10-11Change From Baseline in Mean Daytime Systolic Blood Pressure (SBP) as Measured by Ambulatory Blood Pressure Monitoring (ABPM) at Day 28 | Phase 2 | Completed | Drug: placebo, PF-00489791, PF-00489791, PF-00489791 | Hypertension | 135 | 2007-02-27 | 2008-01-28actual | — | 2021-10-11 |
| PFE | Pfizer | $155.3B | Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino PatientsNCT01200407results2021-08-17observationalNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | — | Terminatedsponsor's stated reason: The requirement for Post Marketing Surveillance was lifted by the Philippine FDA | Drug: Amlodipine + Olmesartan medoxomil | Hypertension | 615 | 2010-06-09 | 2014-01-04actual | — | 2021-08-17 |
| NVS | Novartis | — | A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential HypertensionNCT00667719results2021-06-07Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Death | Phase 3 | Completed | Drug: Aliskiren, Amlodipine, Hydrochlorothiazide | Essential Hypertension | 564 | 2008-06-05 | 2009-10-05actual | — | 2021-06-07 |
| NVS | Novartis | — | A Study to Evaluate the Effects of LCI699 on Cortisol in Participants With HypertensionNCT00817414results2021-06-02Maximum Tolerated Dose (MTD) of LCI699 With Respect to Effect on the Adrenocorticotropic Hormone (ACTH)-Stimulated Cortisol Response Following ACTH Stimulation in Hypertensive Participants | Phase 2 | Completed | Drug: LCI699-matching placebo, LCI699 | Hypertension | 63 | 2009-01-14 | 2009-08-12actual | — | 2021-06-02 |
| NVS | Novartis | — | A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant HypertensionNCT00817635results2021-06-02Change From Baseline in MSSBP at Week 8 Last Observation Carried Forward (LOCF) | Phase 2 | Completed | Drug: LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo | Hypertension | 155 | 2008-12-22 | 2009-10-13actual | — | 2021-06-02 |
| 000100.KS | Yuhan Corporation | $4.2B | High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and HypertensionNCT03474562Change from baseline to week 24 in homeostasis model assessment for insulin resistance (HOMA-IR) | Phase 4 | Completed | Drug: Duowell®, Monorova® + Amlopin® | ASCVD, Impaired Fasting Glucose, Hypertension | 100 | 2018-04-03 | 2019-06-07actual | — | 2021-06-02 |
| 000100.KS | Yuhan Corporation | $4.2B | Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With HypertensionNCT03267329Changes from baseline in mean central systolic blood pressure | Phase 4 | Completed | Drug: Duowell®, Telmisartan | Hypertension, Dyslipidemia | 80 | 2017-09-11 | 2020-09-02actual | — | 2021-04-06 |
| BSX | Boston Scientific Corporation | $73.1B | Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)NCT02392351results2019-10-04OBSERVATIONAL: Change (Mean Reduction) in Average 24-hour Ambulatory Systolic Blood Pressure (ASBP) Through 8 Weeks | Not applicable | Completed | Device: Renal Denervation (Vessix), Renal Angiography | Hypertension | 51 | Apr 2015 | 2017-09-07actual | — | 2021-02-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Hypertension is matched — 5 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Hypertension
- Essential Hypertension
- Uncontrolled Hypertension
- High Blood Pressure
- Resistant Hypertension
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Hypertension” (a text search, wider than this page)